Genscript Biotech (1548.HK) Stock Price
Genscript Biotech Price
Revenue has compounded at 25.0% per year over the past 13 years to 959.53 M USD. Earnings per share have grown at 41.7% per year over the last 11 years. Genscript Biotech's net margin stands at -55.5%, up from -68.1% several years earlier. Genscript Biotech currently offers a dividend yield of about 0.31%. The payout ratio is around 10% of earnings. Analysts set a median price target of 2.53 USD, implying 34.4% below the current price. Of 16 analysts, 15 rate the stock a buy — an overall Buy consensus.
Genscript Biotech stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Genscript Biotech business model & stock analysis
Frequently asked questions about Genscript Biotech
The business model of Genscript Biotech Corp focuses on providing integrated solutions for life sciences research and drug discovery. The company offers a comprehensive range of products and services, including gene synthesis, protein expression, antibody development, and molecular diagnostics. Genscript Biotech Corp aims to accelerate biological research and development by providing high-quality and cost-effective solutions to scientists worldwide. Through its innovative technologies and expertise, the company has gained a strong reputation in the biotech industry. Genscript Biotech Corp continually strives to enhance its capabilities and expand its product portfolio to meet the evolving needs of the scientific community.
Genscript Biotech Corp is primarily active in the biotechnology industry.
The main competitors of Genscript Biotech Corp in the market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, and Sartorius AG.
Genscript Biotech Corp is a leading biotechnology company with a rich history and background. Established in 2002, the company specializes in providing high-quality services and products in the field of life sciences research. Genscript is dedicated to enabling advancements in scientific discoveries and breakthroughs through its expertise in gene synthesis, custom protein production, antibody development, and many other gene-related services. With its state-of-the-art facilities and a global customer base, Genscript has become a trusted partner for researchers and pharmaceutical companies worldwide. The company's commitment to innovation and excellence has helped propel it to the forefront of the biotech industry, making Genscript Biotech Corp a reliable choice for investors seeking opportunities in this dynamic sector.
Genscript Biotech Corp has achieved several significant milestones. As a leading biotechnology company, Genscript has made remarkable strides in the field. Notably, the company successfully completed the genome synthesis of the E. coli bacterium in 2010, which was a groundbreaking achievement. In 2015, Genscript became the first Chinese biotech firm to be listed on the Hong Kong Stock Exchange, marking a significant milestone for the company. Moreover, Genscript has continuously expanded its portfolio of services and products, catering to various research areas and providing innovative solutions to the scientific community. With such achievements, Genscript Biotech Corp stands as a prominent player in the biotech industry.
Genscript Biotech Corp is primarily present in several countries and regions across the globe. The company has a strong foothold in China, where its headquarters are located. Additionally, Genscript Biotech Corp has a significant presence in the United States, with offices and operations spread across various states. The company has also established a strong international presence, with operations and collaborations in Europe, Asia, and other regions worldwide. With its global reach, Genscript Biotech Corp continues to expand its presence and deliver innovative solutions in the field of biotechnology.
Genscript Biotech Corp represents values of innovation, collaboration, and commitment to scientific advancement. With a strong corporate philosophy centered around providing quality products and services, Genscript strives to enhance the understanding and application of biotechnology worldwide. The company is dedicated to delivering cutting-edge research tools, custom solutions, and high-quality services to enable scientists and researchers in various fields. Genscript Biotech Corp aims to foster a culture of excellence, integrity, and customer-centricity, positioning itself as a global leader in the biotech industry.
Analysts currently set an average price target of 2.67 USD for the Genscript Biotech stock (median: 2.53 USD), implying -30.6 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Genscript Biotech stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genscript Biotech to generate revenue of 893.85 M USD and earnings per share of 0.01 USD.
Converted at the current exchange rate, the Genscript Biotech share trades at 3.43 EUR (3.85 USD).
The Genscript Biotech share (1548.HK) is listed on 4 stock exchanges, including: Hongkong (HKEX) (1548.HK), Frankfurt (G51.F), München (G51.MU).
GenScript Biotech Corp is a leading company in the biotech industry that specializes in the development and manufacture of high-quality biological products and services. The company offers a wide range of products and services, including DNA synthesis, protein production, antibody production, cell line development, and diagnostic tools. The company's divisions include proprietary products, manufacturing, and CRO (Contract Research Organization). Proprietary products contribute a large portion of the company's revenue and include various products such as CRISPR/Cas9 kits, DNA sequencing, protein analysis, and antibody services. GenScript Biotech's manufacturing business model is highly tailored to customer needs. It is based on critical procedures that incorporate proven expertise and patented technologies. The model includes a targeted approach to developing the necessary production processes, quality controls at every step of the manufacturing process, and support throughout the customer's entire lifecycle. An essential goal of the company is to support customers in every phase of the manufacturing process to ensure smooth and successful production. The Contract Research Organization (CRO) division of GenScript Biotech focuses on supporting customers in early stages of biological research or clinical trials. Through partnerships with the company, customers are supported through services such as protein engineering, cell line development, cell therapy, in vivo services, and pharmaceutical development. The company also offers a variety of diagnostic solutions and laboratory services. Examples include the development of cellular assays, reagent manufacturing, and DNA sequencing services. Overall, GenScript Biotech Corp is strongly focused on providing rapid and flexible service to its customers by offering a wide range of biopharmaceuticals, diagnostic tools, and laboratory services. The company has a global presence with offices in China, the USA, Europe, Japan, and Singapore. As a company that prioritizes innovation and quality, GenScript Biotech holds a strong position in the biotechnology market. With its various divisions and high-quality offering of products and services, the company provides its customers with a valuable partner to achieve their goals in biotechnology.
The expected revenue of Genscript Biotech is 893.85 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Genscript Biotech is 28.41 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Genscript Biotech is currently 302.24. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genscript Biotech stock.
The price-to-sales ratio (P/S) of Genscript Biotech is currently 9.60. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genscript Biotech stock.
The Eulerpool Quality Score for Genscript Biotech is 5/10.
The ISIN of Genscript Biotech is KYG3825B1059. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Genscript Biotech is A2ACSB. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Genscript Biotech is 1548.HK. The ticker symbol is used to trade Genscript Biotech shares on the stock exchange.
Genscript Biotech stock
Genscript Biotech Peer Group
Genscript Biotech Ticker
Genscript Biotech FIGI
All fundamentals and in-depth analysis of Genscript Biotech
Our stock analysis for Genscript Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genscript Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.